Wolters Kluwer completes Eastern European rollout of Libra legal AI workspace with four-country launch
Libra by Wolters Kluwer now live in Czech Republic, Slovakia, Hungary and Romania, expanding European footprint Alphen aan den Rijn, Netherlands–(BUSINESS... Read more.
The Next Wave in FinTech: AI & Human Synergy Advisory Model by CUSP Wealth
Discover how CUSP Wealth powers its hybrid advisory model, making investing and wealth advisory clear and accessible in the UAE. DUBAI, United Arab Emirates–(BUSINESS... Read more.
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options... Read more.
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative... Read more.
Hytera Introduces PNC660 450MHz: New Device Certified for Power and Energy Mission-Critical Networks
BARCELONA, Spain–(BUSINESS WIRE)–#5Gnetwork–Hytera Communications, a leading global provider of critical communications technologies and solutions,... Read more.
H2O.ai and CTC Global Singapore Have Partnered Together To Democratize Agentic AI Across APAC
SINGAPORE–(BUSINESS WIRE)–H2O.ai, the leading open-source AI platform company, and CTC Global Singapore, a trusted technology integrator across Asia... Read more.
Liberty Energy Inc. Announces Pricing of Upsized $475.0 Million Convertible Senior Notes Offering
DENVER–(BUSINESS WIRE)–Liberty Energy Inc. (NYSE: LBRT) (“Liberty”) today announced the pricing of, and that it has agreed to sell, $475.0 million... Read more.
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indication of “gastrointestinal stromal tumor that has progressed... Read more.
Anaergia Reports Positive Adjusted EBITDA1 and Strong Revenue Growth in Fiscal 2025
Fourth Quarter Revenue Increased 111% and Gross Profit Expanded 79% Year-over-Year BURLINGTON, Ontario–(BUSINESS WIRE)–$ANRG #ANRG–Anaergia Inc.... Read more.
GTJAI (1788.HK) Achieved Record-High Revenue in 2025 with Profitability Making a Leapfrog Improvement
Performance Summary: Revenue increased by 41% to HK$6.230 billion, setting a new record high Net profit after tax surged by 287% to HK$1.345 billion Total assets... Read more.